Global Pharmaceutical Contract Manufacturing Market to Reach US$40.7 Billion by 2015, According to a New Report

Global Pharmaceutical Contract Manufacturing Market to Reach US$40.7 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Pharmaceutical Contract Manufacturing markets. The global market for pharmaceutical contract manufacturing is forecast to reach US$40.7 billion by the year 2015. Key factors propelling market growth include growing demand for new drugs, increasing need for R&D productivity and efficiency, drive towards cutting costs, and huge number of biotech companies that lack internal manufacturing capabilities.

The global market for pharmaceutical contract manufacturing witnessed robust growth in recent years, and the future continues to hold tremendous prospects for the industry. With the onset of global economic recession, several countries in the developed world began scouting for ways to minimize expenditure on drugs. Resultantly, pharmaceutical companies were compelled to seek ways of minimizing cost of drugs, which in turn forced them to evaluate opportunities for manufacturing outsourcing. Despite tough times faced by companies in the pharmaceutical contract manufacturing industry during the recession, overall market maintained a positive growth posting only a moderate slowdown in growth. However, a drop in venture capital funding due to the recession has compelled many pharmaceutical and biotechnology companies to cut down on spending, affecting the fortunes of contract manufacturers worldwide. As a result, several projects were kept on hold and new project starts were delayed, cascading the impact of the pharmaceutical industry to the outsourcing industry as well.

Global pharma industry has been witnessing drastic changes such as increasing competition in generic markets, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental pressure to reduce drug prices. Further, the drug development process is known to extend over a period ranging from 8 to 15 years, and the cost of bringing out a single new molecule into the market is more than US$800 million. With limited new blockbuster drugs, the decisive factors for growth and sustainability are faster new drug development and cost containment. When the drug gets regulatory approval, pharma companies will require large quantities of product supplies for marketing and distribution. Given the considerable timelines of drug development, it is not only difficult to project a company's manufacturing needs but also challenging to procure extensive capital requirements. As a result, PCM outsourcing emerged to bail out pharma companies from these manufacturing uncertainties. Initially, it gained popularity in the US and Western Europe. Over the years, PCM outsourcing shifted its base to low-cost nations.

Today, manufacturing capacity constraints are only one of the reasons for outsourcing. Pharmaceutical manufacturing entails sophisticated technology (cGMP synthesis and scale up, impurity profiling, lyophilization) and strict regulatory compliance (good manufacturing practices - GMP). Outsourcing such activities to Contract Manufacturing Organizations (CMOs) enables a pharma company to expedite its R&D, and thus realize the potential revenues. Moreover, CMOs are increasingly offering a wide range of value-added services, which make PCMO an indispensable opportunity to pharma companies.

The US represents the largest regional market for Pharmaceutical Contract Manufacturing worldwide, as stated by the new market research report on Pharmaceutical Contract Manufacturing. Europe trails behind the US. However, future growth in the market is expected to emanate from developing regions, such as Asia-Pacific. Japanese market for Pharmaceutical Contract Manufacturing alone is projected to register a compounded annual growth rate of 12.8% during the analysis period. Segment-wise, solid dosage forms represents the largest segment. The market for liquid dosage forms is projected to record a compounded annual growth rate of close to 6.0% during the analysis period.

Major players profiled in the report include Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, HAUPT Pharma AG, Jubilant Life Sciences Limited, Kemwell Pvt. Ltd, NextPharma, Nipro Corp., Patheon Inc., Royal DSM N.V., among others.

The research report titled "Pharmaceutical Contract Manufacturing: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the pharmaceutical contract manufacturing markets, impact of the recession on the market, current market trends, key growth drivers, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for pharmaceutical contract manufacturing market for the years 2007 through 2015 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key product segments analyzed include Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions). Also, a seven-year (2000-2006) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Pharmaceutical_Contract_Manufacturing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.